科学出版物
Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice.
Muraoka D, Moi ML, Muto O, et al. (2024) NPJ Vaccines Sep 18;9(1):173.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, et al. (2023) Int J Cancer. Jun 15;152(12):2554-2566
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.
Muraoka D, Harada N, Shiku H, Akiyoshi K. (2022) J Control Release. Jul;347:175-182
Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein.
Muraoka D, Situo D, Sawada SI, Akiyoshi K, Harada N, Ikeda H.(2020) Vaccine. Nov 17;38(49):7697-7701
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Muraoka D, Seo N, Hayashi T, Tahara Y, et al. (2019) J Clin Invest. 129(3):1278-1294.
Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.
Muraoka D, Harada N, Hayashi T, et al. (2014) ACS Nano. Sep 23;8(9):9209-18